Trial Profile
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2022
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin; Doxorubicin; Etoposide; Vincristine
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Nov 2017 Status changed from active, no longer recruiting to completed.
- 09 Sep 2015 Status changed from recruiting to active, no longer recruiting; according to an abstract presented at the 16th World Conference on Lung Cancer.
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer